BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

South Korea

SHP Forges Strategic South Korea Ties to Drive AI-Led Innovation in Primary Care

The 10th Asia Pacific Primary Care Research Conference (APPCRC) 2025 commenced at the Academia, SGH Campus, was jointly hosted by SingHealth Po...

June 19, 2025 | News

LOTTE BIOLOGICS Expands Global CDMO Footprint with Antibody Therapeutics Deal with Ottimo Pharma

Expanding track record by signing contracts with various global companies across Asia and Europe LOTTE BIOLOGICS announced on June 19, 2025 that it ha...

June 19, 2025 | News

Cytiva’s $1.6B Expansion Across 3 Continents to Boost Bioprocessing Supply

Faster delivery and productivity gains available thanks to expanded manufacturing capacity in chromatography resins, filtration, single-use bags and ...

June 12, 2025 | News

Sweden’s Salipro Biotech Partners with South Korea’s Daewoong Pharmaceutical to Target Challenging Drug Discovery

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance...

June 12, 2025 | News

Samsung Bioepis Partners with NIPRO to Expand Biosimilar Access in Japan

Samsung Bioepis expands its presence in Japanese market through partnership with NIPRO Corporation Marks a step forward in widening treatments options a...

June 09, 2025 | News

CorestemChemon's Neuronata-R® Shows Promising Efficacy in Early-Stage ALS, Sets Sights on Accelerated FDA Approval

Neuronata-R®, an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis (ALS), has demonstrated meaningfu...

May 30, 2025 | News

Huonslab Completes Patient Enrollment for Pivotal Phase 1 Trial of HLB3-002 in South Korea

Phase 1 Pivotal Study in Korea for HLB3-002 Plans to apply for marketing approval with the MFDS by the 2H 2025 -Huonslab Co., Ltd. (&ldq...

May 27, 2025 | News

Celltrion’s YUFLYMA® Wins Expanded Interchangeability Status for All Humira® Dosage Forms in the U.S.

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] Cellt...

May 26, 2025 | News

Celltrion’s YUFLYMA® Granted Full FDA Interchangeability with Humira® Across All Dosage Forms

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] Cellt...

May 22, 2025 | News

SK Bioscience Wins Supreme Court Patent Battle Against Pfizer Over Pneumococcal Vaccine

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that it the Supreme C...

May 22, 2025 | News

IDT Biologika Ramps Up Global CDMO Expansion Following SK Bioscience Acquisition

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that IDT Biologika, a...

May 21, 2025 | News

Lunit Expands U.S. Footprint with AI-Powered Breast Cancer Screening at Over 200 Sites

Building on Volpara's breast health expertise, Lunit strengthens its U.S. presence—now delivering AI-powered breast cancer screening across 200 imagi...

May 20, 2025 | News

Thermo Fisher Scientific Opens Cell and Gene Therapy Vision Center in South Korea

— Thermo Fisher Scientific, the world leader in serving science, has announced the official opening of its new Cell and Gene Therapy (CGT) Vision Cen...

May 15, 2025 | News

Agilent and Ubix Therapeutics Join Forces to Advance Targeted Cancer Therapies in South Korea

Research focuses on targeted protein degradation and antibody-drug conjugate as promising modalities for developing next-generation cancer therapies ...

May 15, 2025 | News

Stay Connected